Wu Yuchen, Sun Xuefei, Liu Jing, Qian Jun, Bai Xueyan, Chen Yuedan, Liu Yuanbo
Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050 China.
Chin Neurosurg J. 2018 Jan 8;4:1. doi: 10.1186/s41016-017-0106-3. eCollection 2018.
Primary central nervous system lymphoma(PCNSL) is a rare kind of non-Hodgkin lymphoma. Rituximab combined with high-dose methotrexate, cytarabine and dexamethasone (R-MAD regimen) were reported effective for PCNSL patients. Rituximab can cause several side effects, including fever, chills and rigors.
In this case report, we demonstrate rituximab-induced interstitial pneumonitis in a PCNSL patient who has been treated with R-MAD regimen. The patient recovered after treatment and she remains complete remission after following consolidation chemotherapy.
Here is no report of potential fatal complications of Rituximab like interstitial pneumonitis nowadays in PCNSL patients. As Rituximab is widely used, physicians should raise their awareness of this rare complication and detect RTX-ILD in early stage.
原发性中枢神经系统淋巴瘤（PCNSL）是一种罕见的非霍奇金淋巴瘤。据报道，利妥昔单抗联合大剂量甲氨蝶呤、阿糖胞苷和地塞米松（R-MAD方案）对PCNSL患者有效。利妥昔单抗可引起多种副作用，包括发热、寒战和畏寒。
在本病例报告中，我们展示了一名接受R-MAD方案治疗的PCNSL患者发生利妥昔单抗诱导的间质性肺炎。患者经治疗后康复，巩固化疗后仍处于完全缓解状态。
目前尚无关于PCNSL患者中利妥昔单抗潜在致命并发症如间质性肺炎的报道。由于利妥昔单抗被广泛使用，医生应提高对这种罕见并发症的认识，并早期发现利妥昔单抗诱导的间质性肺炎（RTX-ILD）。
